India Pharma Outlook Team | Friday, 06 March 2026
Alembic Pharmaceuticals has made an important milestone with the sale of its initial branded antimicrobial medication, Pivya (pivmecillinam), through a prescription-based channel. The introduction of Pivya was designed to provide healthcare practitioners with an effective and safe treatment option for women who experience uncomplicated urinary tract infections (UTI).
Following the recent commercial launch of Pivya into the US market, Alembic Therapeutics is marketing Pivya as its first-line oral antibiotic. As the fully owned subsidiary of Alembic Pharmaceuticals, Alembic Therapeutics will be the sole distributor of Pivya and will assist with clinical development and product promotion.
Pivya is the first new product defined as an oral antibiotic on the market for decorating manufacturers' shelves within the last ten years. This represents a tremendous opportunity for Alembic Pharmaceuticals to fill the gap in the market, as Pivya has a good safety record that has been verified by physicians and data supporting its efficacy.
Also Read: How Global Capability Centers are Shaping the Future of Biometrics
Alembic plans to utilize this new offering to fill a significant need in the UTI space with the ultimate goal of providing women who suffer from uUTIs with effective therapy options.
Pranav Amin, Chief Executive Officer of Alembic Pharmaceuticals, said, “The successful launch of Pivya marks an exciting moment in our journey to provide high-quality, accessible treatments. We are committed to addressing the needs of patients globally, and this milestone reinforces our dedication to advancing healthcare through innovation and excellence.”
The successful launch of Pivya demonstrates the company's growing capabilities in bringing quality therapeutics to global markets and fortifying the Alembic's continued growth.
